Current ideas in COVID vaccines

Tande AJ, Pollock BD, Shah ND,et al. mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months. Infect Control Hosp Epidemiol. 2021;6:1-3.

Tsang NNY, So HC, Cowling BJ, et al. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421-34.

Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalization and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303-12.

Shrestha NK, Burke PC, Nowacki AS, et al. Effectiveness of the coronavirus disease 2019 (COVID-19) bivalent vaccine. Open Forum Infectious Diseases IDSA. https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofad209/7131292 2023. Accessed May 15, 2023.

Lin DY, Xu Y, Gu Y, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med. 2023;388(8):764-66.

Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023; https://doi.org/10.1016/S1473-3099(23)00122-6. Accessed May 15, 2023.

Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19–associated hospitalization and critical illness among adults with and without immunocompromising conditionsvision network, September 2022-April 2023. Morb Mortal Wkly Rep. 2023;72(21):579-88.